Causes and consequences of the autoimmune lymphoproliferative syndrome

References

• Sneller MC, Wang J, Dale JK, Strober W, Middelton LA, Choi Y, et al. Clinical, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis. Blood 1997;89:1341–1348.
   PubMed Web of Science ®Google Scholar
• Straus SE, Sneller M, Lenardo MJ, Puck JM, Strober W. An inherited disorder of lymphocyte apoptosis: the autoimmune lymphoproliferative syndrome. Ann Intern Med 1999; 130:591–601.
   PubMed Web of Science ®Google Scholar
• Rioux JD, Abbas AK. Paths to understanding the genetic basis of autoimmune disease. Nature 2005 Jun 2;435(7042): 584–589.
   PubMed Web of Science ®Google Scholar
• Yonehara S, Ishii A, Yonehara M. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med 1989;169(5):1747–1756.
   PubMed Web of Science ®Google Scholar
• Lenardo MJ. Introduction: The molecular regulation of lymphocyte apoptosis. Sem in Immunol 1997;9:1–5.
   PubMedGoogle Scholar
• Debatin K, Stahne K, Fulda S, et al. Apoptosis in hema-tological disorders. Sem in Cancer Biol 2003;:149–158.
   PubMed Web of Science ®Google Scholar
• Siegel RM, Muppidi JR, Sarker M, Lobito A, Jen M, Martin D, Straus SE, Lenardo MJ. SPOTS: Signaling protein oligomeric transduction structures are early mediators of death receptor-induced apoptosis at the plasma membrane. J Cell Biol 2004;167:735–744.
   PubMed Web of Science ®Google Scholar
• Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S:. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992;356:314–317.
   PubMed Web of Science ®Google Scholar
• Cohen PL, Eisenberg RA:. Lpr and gld: Single gene models of systemic autoimmunity and lymphoproliferative disease. Ann Rev Immunol 1991;9:243–269.
   PubMed Web of Science ®Google Scholar
• Sneller MC, Straus SE, Jaffe ES, Jaffe JS, Fleisher TA, Stetler-Stevenson M, et al. A novel lymphoproliferative/autoimmune syndrome resembling murine lpr/gld disease. J Chin Invest 1992;90:334–341.
   PubMed Web of Science ®Google Scholar
• Fisher GH, Rosenberg FJ, Straus SE, Dale JK, Middleton LA, Lin AY, et al. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 1995;81:935–946.
   PubMed Web of Science ®Google Scholar
• Rieux-Laucat F, Blachere S, Danielan S, De Villartay JP, Oleastro M, Solary E, Bader-Meunier B, Arkwright P, Pondare C, Bernaudin F, Chapel H, Nielsen S, Berrah M, Fischer A, Le Deist F. Lymphoproliferative syndrome with autoimmunity: A possible genetic basis for dominant expression of the clinical manifestations. Blood 1999;94:2575–2582.
   PubMed Web of Science ®Google Scholar
• Canale VC, Smith CH. Chronic lymphadenopathy simulating malignant lymphoma. J Pediatr 1967;70:891–899.
   PubMed Web of Science ®Google Scholar
• Wang J, Zheng L, Lobito A, Chan FK, Dale J, Sneller M, et al. Inherited human Caspase 10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type II. Cell 1999;98:47–58.
   PubMed Web of Science ®Google Scholar
• Chun HJ, Zheng L, Ahmad M, Wang J, Speirs CK, Siegel RM, Dale JK, Puck J, Davis J, Hall CG, Skoda-Smith S, Atkinson TP, Straus SE, Lenardo MJ. Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency. Nature 2002;419: 395–399.
   PubMed Web of Science ®Google Scholar
• van der Werff ten Bosch JE, Otten J, Thielemans K. Autoimmune lymphoproliferative syndrome type III: An indefinite disorder. Leuk lymphoma 2001;41:55–65.
   PubMed Web of Science ®Google Scholar
• Puck JM, Straus SE. Somatic mutations — not just for cancer anymore (Perspective). NEJM 2004;351:1388–1390.
   PubMed Web of Science ®Google Scholar
• Holzelova E, Vonarbourg C, Stolzenberg MC, et al. Auto-immune lymphoproliferative syndrome with somatic Fas mutations. NEJM 2004;351:1409–14194.
   PubMed Web of Science ®Google Scholar
• Sneller MC, Dale JK, Straus SE. Autoimmune lymphoproliferative syndrome. Curr Opin Rheumatol 2003;15:417–421.
   PubMed Web of Science ®Google Scholar
• Avila NA, Dwyer AJ, Dale JK, Lopatin UA, Sneller MC, Jaffe ES, et al. Autoimmune lymphoproliferative syndrome: A syndrome associated with inherited genetic defects that impair lymphocytic apoptosis — CT and US features. Radiology 1999;212:257–263.
   PubMed Web of Science ®Google Scholar
• Teachey DT, Manno CS, Axsom KM, Andrews T, Choi JK, Greenbaum BH, McMann JM, Sullivan KE, Travis SF, Grupp SA. Unmasking Evans syndrome: T cell phenotype and apoptotic response reveal autoimmune lymphoproliferative syndrome (ALPS). Blood 2005;105:2443–2448.
   PubMed Web of Science ®Google Scholar
• Maric I, Pittaluga S, Dale JK, Niemela JE, Delsol G, Diment J, Rosai J, Raffeld M, Puck JM, Straus SE, Jaffe E. Histologic Features of Sinus Histiocytosis With Massive Lymphadenopathy in Patients With Autoimmune Lympho-proliferative Syndrome. Am J Surg Pathol 2005 Jul;29(7):903–911.
   PubMed Web of Science ®Google Scholar
• Bleesing JJ, Brown MR, Straus SE, Dale JK, Siegel RM, Johnson M, Lenardo MJ, Puck JM, Fleisher TA. Immuno-phenotypic profiles in families with autoimmune lymphopro-liferative syndrome. Blood 2001;98:2466–2473.
   PubMed Web of Science ®Google Scholar
• Lim MS, Straus SE, Dale JK, Fleisher TA, Stetler-Stevenson M, Strober W, et al. Pathological findings in human autoimmune lymphoproliferative syndrome. Am J Pathol 1998;153:1541–1550.
   PubMed Web of Science ®Google Scholar
• Fuss IJ, Strober W, Dale JK, Fritz S, Pearlstein GR, Puck JM, et al. Characteristic T helper 2 T cell cytokine abnormalities in autoimmune lymphoproliferative syndrome, a syndrome marked by defective apoptosis and humoral autoimmunity. J Immunol 1997158:1912-1918.
   PubMed Web of Science ®Google Scholar
• Stroncek DF, Carter LB, Procter JL, Dale JK, Straus SE. RBC autoantibodies in autoimmune lymphoproliferative syndrome. Transfusion 2001;41:18–23.
   PubMed Web of Science ®Google Scholar
• Kwon SW, Procter J, Dale JK, Straus SE, Stroncek DF. Neutrophil and platelet antibodies in autoimmune lympho-proliferative syndrome. Vox Sang 2003;85:307–312.
   PubMed Web of Science ®Google Scholar
• Fang BS, Sneller MC, Straus SE, Frenkel L, Dale JK, Rick ME. Report of a factor VIII inhibitor in a patient with autoimmune lymphoproliferative syndrome. Am J Hematol 2000;64:214–217.
   PubMed Web of Science ®Google Scholar
• Aspinall Al, Pinto A, Auer IA, Bridges P, Luider J, Dimnik L, et al. Identification of new Fas mutations in a patient with autoimmune lymphoproliferative syndrome (ALPS) and eosinophilia. Blood Cells Mol Dis 1999;25:227–238.
   PubMed Web of Science ®Google Scholar
• Bader-Munier B, Rieux-Laucat F, et al. Dyserythropoiesis associated with a fas-deficient condition in childhood. Br J Hematol 2000;108:300–304.
   PubMed Web of Science ®Google Scholar
• Jackson CE, Puck JM. Autoimmune lymphoproliferative syndrome, a disorder of apoptosis. Curr Opin Pediatr 1999;6:521–527.
   Google Scholar
• Fisher GH, Rosenberg FJ, Straus SE, Dale JK, Middleton LA, Lin AY, et al. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 1995;81:935–946.
   PubMed Web of Science ®Google Scholar
• Lopatin U, Yao X, Williams RK, Bleesing jj, Dale JK, Wong D, Teruya-Feldstein J, Fritz S, Morrow MR, Fuss I, Sneller MC, Raffeld M, Fleisher TA, Puck JM, Strober W, Jaffe ES, Straus SE. Increases in circulating and lymphoid tissue interleukin-10 in autoimmune lymphoproliferative syndrome are associated with disease expression. Blood 2001 May 15;97(10): 3161–3170.
   PubMed Web of Science ®Google Scholar
• Straus SE, Jaffe ES, Puck JM, Dale JK, Elkon KB, et al. The development of lymphomas in families with Autoimmune Lymphoproliferative Syndrome (ALPS) with germline Fas mutations and defective lymphocyte apoptosis. Blood 2001;98:194–200.
   PubMed Web of Science ®Google Scholar
• Poppema S, Maggio E, van den Berg A. Development of lymphoma in ALPS and its relationship to Fas gene mutations. Leuk Lymphoma 2004;45:423–431.
   PubMed Web of Science ®Google Scholar
• Muschen M, Warskulat U, Beckmann MW. Defining CD95 as a tumor suppressor gene. J Mol Med 2000;78: 312–325.
   PubMed Web of Science ®Google Scholar
• Muschen M, Re D, Brauninger A, Wolf J, Hansmann ML, Diehl V, Kuppers R, Rajewsky K. Somatic mutations of the CD95 gene in Hodgkin and Reed-Sternberg cells. Cancer Res 2000;60:5640–5643.
   PubMed Web of Science ®Google Scholar
• Shin MS, Kim HS, Kang CS, et al. Inactivating mutations of CAS P10 gene in non-Hodgkin lymphomas. Blood 2002;99:4094–4099.
   PubMed Web of Science ®Google Scholar
• van der Werff ten Bosch JE, Demanet C, Balduck N, Bakkus MH, De Raeve H, Desprechins B, et al. Reversion of autoimmune lymphoproliferative syndrome with an antima-larial drug: Preliminary results of a clinical cohort study and molecular observations. Br J Haematol 2002;117:176–188.
   PubMed Web of Science ®Google Scholar
• Lutwick L. Infections in asplenic patients. From principles and practice of infectious diseases. 6th ed. In: Mandell, Douglas, Bennett, editors. Elsevier Churchill Livingstone; Philadelphia, PA: 2005. p 3524–3535.
   Google Scholar
• Heelan BT, Tormey V, Amlot P, Payne E, Mehta A, Webster AD. Effect of anti-CD20 (rituximab) on resistant thrombocy-topenia in autoimmune lymphoproliferative syndrome. Br J Haematol 2002;118:1078–1081.
   PubMed Web of Science ®Google Scholar
• Rao VK, Dale J, Hurley H, Dugan F, Tretler J, Straus SE. Use of mycophenolate mofetil in Children with chronic, refractory immune cytopenias associated with autoimmune lymphopro-liferative syndrome (ALPS). Br J Haemat 2005; 129:534–538.
   PubMed Web of Science ®Google Scholar
• Lucignani G, Paganelli G, Bomabardieri E. The use of standardized uptake values for assessing FDG uptake with PET in oncology: A clinical perspective. Nucl Med Commun 2004;25:651–656.
   PubMed Web of Science ®Google Scholar
• Burton C, Ell P, Linch D. The role of PET imaging in lymphoma. Br J Haematol 2004;126:772–784.
   PubMed Web of Science ®Google Scholar
• Benkerrou M, Le Deist F, de Villartay JP, Caillat-Zucman S, Rieux-Laucat F, Jabado N, et al. Correction of Fas (CD95) deficiency by haploidentical bone marrow transplantation. Eur J Immunol 1997;27: 2043–2047.
   PubMed Web of Science ®Google Scholar
• Sleight BJ, Prasad VS, DeLaat C, Steele P, Ballard E, Arceci RJ, et al. Correction of autoimmune lymphoproliferative syndrome by bone marrow transplantation. Bone Marrow Transplant 1998;22:375–380.
   PubMed Web of Science ®Google Scholar
• Jackson CE, Fischer RE, Hsu AP, Anderson SM, Choi Y, Wang J, Dale JK, Fleisher TA, Middelton LA, Sneller MC, Lenardo MJ, Straus SE, Puck JM. Autoimmune lymphopro-liferative syndrome with defective Fas: Genotype influences penetrance. Am J Hum Genet 1999;64:1002–1014.
   PubMed Web of Science ®Google Scholar
• van der Burg M, de Groot R, Comans-Bitter WM, den Hollander JC, Hooijkaas H, Neijens HJ, Berger RM, Oranje AP, Langerak AW, van Dongen H. Autoimmune lymphoproliferative syndrome (ALPS) in a child from consanguineous parents: A dominant or recessive disease? Pediatr Res 2000;47: 336–343.
   PubMed Web of Science ®Google Scholar
• Rieux-Laucat F, Deist FL, Fischer A. Autoimmune lympho-proliferative syndromes: Genetic defects of apoptosis pathways (Review). Cell Death Differ 2003;10:124–133.
   PubMed Web of Science ®Google Scholar
• Cines D, Bussel JB. How I Treat: ITP. Blood Jun 7 2005; [Epub ahead of print].
   Google Scholar